Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires 150,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 150,000 shares of the stock in a transaction on Friday, January 17th. The shares were purchased at an average cost of $1.47 per share, with a total value of $220,500.00. Following the transaction, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. This trade represents a 0.07 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost bought 199,072 shares of OPKO Health stock. The shares were acquired at an average price of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were bought at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Stock Performance

Shares of OPK opened at $1.47 on Friday. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.63. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The business’s 50 day moving average is $1.54 and its two-hundred day moving average is $1.51. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.76.

Institutional Trading of OPKO Health

Several institutional investors have recently added to or reduced their stakes in OPK. American Century Companies Inc. acquired a new stake in shares of OPKO Health in the 2nd quarter valued at about $112,000. Hollencrest Capital Management increased its holdings in OPKO Health by 14.0% in the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 11,020 shares during the last quarter. Rubric Capital Management LP raised its stake in OPKO Health by 800.0% during the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after buying an additional 39,486,490 shares in the last quarter. Squarepoint Ops LLC bought a new position in OPKO Health during the 2nd quarter worth approximately $592,000. Finally, Algert Global LLC acquired a new position in shares of OPKO Health in the 2nd quarter worth approximately $44,000. 64.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

OPK has been the subject of several recent research reports. StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Wednesday, January 8th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.